Brenda Motheral, PhD

home / authors / brenda-motheral-phd

Articles

April 1st 2004

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Robert Valuck, PhD, RPH. Author Reply by Emily R. Cox, PhD Brenda Motheral, PhD Doug Mager, BS

December 1st 2003

Verification of a Decision Analytic Model Assumption Using Real-World Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Emily R. Cox, PhD Brenda Motheral, PhD Doug Mager, BS

November 1st 2003

Prescribing COX-2s for Patients New to Cyclo-oxygenase Inhibition Therapy

Emily R. Cox, PhD Brenda Motheral, PhD Mark Frisse, MD* Andrew Behm, PharmD Doug Mager, BS

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Glaucoma | Image credit: Alessandro Grandini - stock.adobe.com

Published: November 21st 2024 | Updated: November 24th 2024

Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions